By Fineline Cube 
Boehringer Ingelheim (BI) announced today the official start‑up of its local manufacturing plan for the diabetes medication Trajenta® (linagliptin) at its human pharmaceutical production facility in Zhangjiang, Pudong. The move marks a pivotal shift from commercial operations to vertical integration of the company’s supply chain in the Chinese market.
Key Highlights
| Item | Detail |
|---|---|
| Product | Trajenta® (linagliptin) |
| Facility | Zhangjiang, Pudong, Shanghai |
| Strategic Goal | Deepen Boehringer’s footprint in China via local production |
| R&D Commitment | > RMB 5 billion over the next 5 years |
| “China Key” Strategy | Pursue earlier or simultaneous approvals for new products/indications in China versus the global market |
Why It Matters
- Supply Chain Resilience – Local manufacturing reduces dependence on imports, ensuring timely availability for China’s 1.4 billion population and the country’s growing diabetes market.
- Cost & Pricing Advantage – Domestic production can lower manufacturing costs and enable more competitive pricing, addressing affordability concerns in China’s tier‑2 and tier‑3 cities.
- Accelerated Innovation – The 5 billion RMB R&D investment will fuel clinical development of next‑generation antidiabetic agents and expanded indications, reinforcing Boehringer’s “China Key” pipeline acceleration.
Looking Ahead
Boehringer Ingelheim plans to leverage its Zhangjiang facility to support both current and future product launches, positioning the company to secure approval for new indications in China ahead of or concurrently with global markets. The strategy underscores the firm’s commitment to the Chinese market as a critical growth engine in the coming decade.
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research‑driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. The company focuses on innovative therapies in cardiometabolic diseases, respiratory disorders, and oncology, among other therapeutic areas.-Fineline Info & Tech